In patients with diabetes mellitus, metformin treatment is associated with reduced mortality and attenuation of cardiovascular risk. As a subanalysis of the Glycometabolic Intervention as adjunct to Primary Coronary Intervention in ST Elevation Myocardial Infarction (GIPS-III) study, we evaluated whether metformin treatment in patients with ST-segment elevation myocardial infarction (STEMI) without diabetes improves the cardiovascular risk profile.A total of 379 patients, without known diabetes, presenting with STEMI were randomly allocated to receive metformin 500 mg twice daily or placebo for 4 months.After 4 months, the cardiovascular risk profile of patients receiving metformin (n=172) was improved compared with placebo (n=174); glycated hemoglobin (5.83

作者：Chris P H, Lexis；Anouk N A, van der Horst-Schrivers；Erik, Lipsic；Mattia A E, Valente；Anneke C, Muller Kobold；Rudolf A, de Boer；Dirk J, van Veldhuisen；Pim, van der Harst；Iwan C C, van der Horst

来源：BMJ open diabetes research & care 2015 年 3卷 1期